The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy
文献类型：期刊论文
| 作者 | Shen, J; Song, GS; An, M; Li, XQ; Wu, N; Ruan, KC; Hu, JQ; Hu, RG |
| 刊名 | BIOMATERIALS
 |
| 出版日期 | 2014 |
| 卷号 | 35期号:1页码:316-326 |
| 关键词 | Anti-tumor activity Apoptotic cell death Bortezomib Drug delivery Mesoporous silica NSCLC |
| 通讯作者 | Hu, RG (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai Key Lab Mol Androl, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.,hu.junqing@dhu.edu.cn ; coryhu@sibs.ac.cn |
| 英文摘要 | Bortezomib (BTZ) is the first clinically approved proteasome inhibitor for treating multiple human malignancies. However, the poor water-solubility and low stability of BTZ and the emergence of tumor resistance have severely restrained its therapeutic efficacy. Herein, we report the application of hollow mesoporous silica nanospheres (HMSNs) in encapsulating BTZ for drug delivery. In in vitro cell viability assay on human NSCLC H1299 cells, the half-maximum inhibiting concentration (IC50) of HMSNs-BTZ was 42% of that for free BTZ in 48 h treatments. In vivo tumor-suppression assay further indicated that HMSNs-BTZ (0.3 mg/kg) showed approximately 1.5 folds stronger anti-tumor activity than free BTZ. Furthermore, we report that more potent induction of cell cycle arrest and apoptotic cell death, along with promoted activation of Caspase 3 and autophagy might mechanistically underlie the improved antitumor efficacy of HMSNs-BTZ. Finally, the tumor-suppressing effect of HMSNs-BTZ was enhanced in the presence of wild-type p53 signaling, suggesting a potential enhancement in clinical efficacy with combined p53 gene therapy and BTZ-based chemotherapy. Therefore, the HMSNs-based nanoparticles are emerging as a promising platform to deliver therapeutic agents for beneficial clinical outcomes through lowering doses and frequency of drug administration and reducing potential side effects. (C) 2013 Elsevier Ltd. All rights reserved. |
| 学科主题 | Engineering; Materials Science |
| 类目[WOS] | Engineering, Biomedical ; Materials Science, Biomaterials |
| 关键词[WOS] | CONTROLLED DRUG-DELIVERY ; MULTIPLE-MYELOMA CELLS ; PROTEASOME INHIBITOR ; FUTURE-DIRECTIONS ; ANTICANCER DRUG ; P53 GENE ; COMBINATION ; APOPTOSIS ; SHELL ; CORE |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000328006100031 |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.143/handle/331003/135]  |
| 专题 | 上海生化细胞研究所_上海生科院生化细胞研究所 |
| 推荐引用方式 GB/T 7714 | Shen, J,Song, GS,An, M,et al. The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy[J]. BIOMATERIALS,2014,35(1):316-326. |
| APA | Shen, J.,Song, GS.,An, M.,Li, XQ.,Wu, N.,...&Hu, RG.(2014).The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy.BIOMATERIALS,35(1),316-326. |
| MLA | Shen, J,et al."The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy".BIOMATERIALS 35.1(2014):316-326. |
入库方式： OAI收割
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。